Mizuho Markets Americas LLC Sells 220,000 Shares of Bristol-Myers Squibb (NYSE:BMY)

Mizuho Markets Americas LLC lessened its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 7.9% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,579,600 shares of the biopharmaceutical company's stock after selling 220,000 shares during the quarter. Bristol-Myers Squibb makes up approximately 2.8% of Mizuho Markets Americas LLC's portfolio, making the stock its 10th biggest position. Mizuho Markets Americas LLC owned 0.13% of Bristol-Myers Squibb worth $133,469,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Capital International Investors grew its holdings in shares of Bristol-Myers Squibb by 14.1% during the 1st quarter. Capital International Investors now owns 70,203,814 shares of the biopharmaceutical company's stock worth $3,807,153,000 after acquiring an additional 8,675,322 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Bristol-Myers Squibb by 77.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 12,547,823 shares of the biopharmaceutical company's stock valued at $680,469,000 after buying an additional 5,461,767 shares during the period. Federated Hermes Inc. boosted its holdings in shares of Bristol-Myers Squibb by 86.3% during the 2nd quarter. Federated Hermes Inc. now owns 7,546,311 shares of the biopharmaceutical company's stock valued at $313,398,000 after buying an additional 3,495,704 shares in the last quarter. Swedbank AB purchased a new stake in shares of Bristol-Myers Squibb in the 1st quarter worth about $158,223,000. Finally, State of Michigan Retirement System increased its stake in shares of Bristol-Myers Squibb by 147.7% in the 2nd quarter. State of Michigan Retirement System now owns 4,767,133 shares of the biopharmaceutical company's stock worth $197,979,000 after acquiring an additional 2,842,400 shares in the last quarter. Institutional investors own 76.41% of the company's stock.

Analysts Set New Price Targets

Several research firms have commented on BMY. Barclays boosted their target price on Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an "underweight" rating in a report on Monday, October 7th. Sanford C. Bernstein initiated coverage on shares of Bristol-Myers Squibb in a report on Thursday, October 17th. They issued a "market perform" rating and a $56.00 target price for the company. Jefferies Financial Group upped their price target on Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a "hold" rating in a report on Wednesday, August 28th. Leerink Partnrs raised Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a report on Tuesday. Finally, TD Cowen upped their price objective on Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a "hold" rating in a research report on Monday, October 7th. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, two have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $54.07.

Insider Activity

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,830 shares of Bristol-Myers Squibb stock in a transaction on Friday, November 1st. The stock was bought at an average cost of $54.67 per share, with a total value of $100,046.10. Following the transaction, the executive vice president now owns 62,109 shares of the company's stock, valued at $3,395,499.03. This represents a 3.04 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the company's stock in a transaction on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the sale, the senior vice president now directly owns 11,760 shares in the company, valued at $654,091.20. This trade represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Stock Down 3.9 %

Bristol-Myers Squibb stock traded down $2.28 during trading hours on Friday, reaching $56.22. The stock had a trading volume of 21,259,228 shares, compared to its average volume of 14,463,189. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.08. The company has a market cap of $114.02 billion, a price-to-earnings ratio of -15.66, a PEG ratio of 15.83 and a beta of 0.44. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. The business's 50 day moving average price is $52.73 and its 200-day moving average price is $47.23.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The company had revenue of $11.89 billion during the quarter, compared to analysts' expectations of $11.26 billion. During the same quarter in the prior year, the company posted $2.00 earnings per share. Bristol-Myers Squibb's revenue for the quarter was up 8.4% compared to the same quarter last year. Sell-side analysts anticipate that Bristol-Myers Squibb will post 0.92 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were paid a dividend of $0.60 per share. The ex-dividend date was Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.27%. Bristol-Myers Squibb's payout ratio is -66.85%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.